Ontology highlight
ABSTRACT: Background
Few studies have characterized the full spectrum of prescription drug use for individuals with multiple sclerosis (MS). The objective of this study was to describe patterns and expenditures for disease-modifying therapies (DMTs) and other prescription drugs among Medicare beneficiaries with MS.Methods
Using Medicare claims data in 2014, we identified a cohort of Medicare beneficiaries with 12 months of continuous eligibility and 3 or more MS-related inpatient, outpatient, or prescription claims. We quantified the number, type, and costs of prescribed DMTs and other medications for MS-related symptoms. Medication costs were calculated according to whether beneficiaries received additional subsidies, which eliminate most out-of-pocket costs.Results
Of 43,28
SUBMITTER: Hartung DM
PROVIDER: S-EPMC9017658 | biostudies-literature | 2022 Mar-Apr
REPOSITORIES: biostudies-literature